BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 197414)

  • 21. Regulation of cyclic AMP metabolism in human platelets. Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins.
    Alvarez R; Taylor A; Fazzari JJ; Jacobs JR
    Mol Pharmacol; 1981 Sep; 20(2):302-9. PubMed ID: 6272089
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets.
    Tateson JE; Moncada S; Vane JR
    Prostaglandins; 1977 Mar; 13(3):389-97. PubMed ID: 191877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclic nucleotides and aggregation in platelets of spontaneously hypertensive rats.
    Hamet P; Fraysse J; Franks DJ
    Circ Res; 1978 Oct; 43(4):583-91. PubMed ID: 210976
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of cyclic nucleotides in platelet function.
    Haslam RJ
    Ciba Found Symp; 1975; 35():121-51. PubMed ID: 179765
    [No Abstract]   [Full Text] [Related]  

  • 26. Mode of action of dipyridamole on human platelets.
    Best LC; McGuire MB; Jones PB; Holland TK; Martin TJ; Preston FE; Segal DS; Russell RG
    Thromb Res; 1979; 16(3-4):367-79. PubMed ID: 229583
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition of platelet adenylate cyclase by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor).
    Haslam RJ; Vanderwel M
    J Biol Chem; 1982 Jun; 257(12):6879-85. PubMed ID: 6177688
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytochemical localization of adenylate cyclase in the dense tubule system of human blood platelets stimulated by forskolin, prostacyclin and prostaglandin D2.
    Cutler LS; Christian CP; Feinstein MB
    Biochim Biophys Acta; 1985 Jun; 845(3):403-10. PubMed ID: 3890960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role of prostaglandins in platelet aggregation in metabolic syndrome].
    Sokolov EI; Lavrenova NIu; Goloborodova IV
    Vestn Ross Akad Med Nauk; 2010; (4):22-6. PubMed ID: 20540350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation.
    Bussolino F; Camussi G
    Prostaglandins; 1980 Nov; 20(5):781-91. PubMed ID: 6258196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.
    Shepherd GL; Lewis PJ; Blair IA; de Mey C; MacDermot J
    Br J Clin Pharmacol; 1983 Jan; 15(1):77-81. PubMed ID: 6342639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia.
    Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S
    Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aggregation and thromboxane formation by platelets and vascular prostacyclin production from BB rats. An animal model for type I diabetes.
    Landgraf-Leurs MM; Landgraf R; Loy A; Weber PC; Herberg LL
    Prostaglandins; 1982 Jul; 24(1):35-46. PubMed ID: 6812171
    [No Abstract]   [Full Text] [Related]  

  • 35. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties.
    Needleman P; Raz A; Minkes MS; Ferrendelli JA; Sprecher H
    Proc Natl Acad Sci U S A; 1979 Feb; 76(2):944-8. PubMed ID: 218223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoplasmic Ca2+ in platelets is controlled by cyclic AMP: antagonism between stimulators and inhibitors of adenylate cyclase.
    Zavoico GB; Feinstein MB
    Biochem Biophys Res Commun; 1984 Apr; 120(2):579-85. PubMed ID: 6329175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclic 3',5'-adenosine monophosphate level and adenylate cyclase activity in human blood platelets during storage in ACD solution.
    Lammerant-Guillemare E; Corcelle-Cerf F; Lammerant J
    Blut; 1977 Apr; 34(4):329-32. PubMed ID: 192396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dissociation of the aggregating effect and the inhibitory effect upon cyclic adenosine monophosphate accumulation by adrenaline and adenosine diphosphate in human platelets.
    Stormorken H; Lyberg T; Hakvaag L; Nakstad B
    Thromb Res; 1987 Feb; 45(4):363-70. PubMed ID: 3033838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet alpha-2 adrenoceptor-mediated primary aggregation and adenylate cyclase inhibition in depressed patients.
    Karege F; Bovier P; Hilleret H; Gaillard JM
    Lancet; 1993 Apr; 341(8851):1029. PubMed ID: 8096917
    [No Abstract]   [Full Text] [Related]  

  • 40. Prostaglandin endoperoxides and thromboxane A2 can induce platelet aggregation in the absence of secretion.
    Charo IF; Feinman RD; Detwiler TC; Smith JB; Ingerman CM; Silver MJ
    Nature; 1977 Sep; 269(5623):66-9. PubMed ID: 895887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.